Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
Recursion Pharmaceuticals reported mixed Q2 2026 results, with revenues declining to $7.67 million and a narrowed net loss of $131.01 million. The company highlighted significant milestones in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results